Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

Sensei Biotherapeutics (NASDAQ: SNSE) will unveil new preclinical data on SNS-103, a monoclonal antibody targeting CD39, at the AACR Annual Meeting 2023 in Orlando from April 14-19, 2023. The presentation titled 'Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment' is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM ET.

Sensei aims to develop therapeutics that activate immune responses against tumors utilizing its TMAb™ platform, and SNS-103 is part of its ongoing research in immune-oncology.

BOSTON, March 7, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced the adoption of a limited duration stockholder rights agreement to protect stockholder interests. This measure is aimed at preventing any entity from gaining control without appropriately compensating all stockholders. Each stockholder will receive one preferred share purchase right for each outstanding share of common stock, effective March 17, 2023. The rights will become exercisable if an acquiring person owns 10% or more of the stock without Company approval. This plan will expire on March 7, 2024. Sensei aims to ensure its Board can make informed decisions about control attempts.

Sensei Biotherapeutics (Nasdaq: SNSE) is set to present at Oppenheimer’s 33rd Annual Healthcare Conference on March 13, 2023. The presentation will begin at 8:00 a.m. ET and be accessible via a webcast on the company’s website. The webcast replay will be available for around 90 days after the event.

Sensei Biotherapeutics focuses on developing next-generation immuno-oncology therapeutics for cancer treatment, with its lead candidate being SNS-101, designed to target the VISTA checkpoint within tumor microenvironments. The company also works on candidates SNS-102 and SNS-103, aimed at different immunosuppressive signals.

Sensei Biotherapeutics (NASDAQ: SNSE) presented preclinical data on SNS-101, a VISTA-blocking antibody, revealing its potential to enhance anti-tumor effects while reducing risks associated with other VISTA antibodies. The new crystal structure data shows that SNS-101 effectively blocks the interaction between VISTA and PSGL-1 in a pH-dependent manner. Preclinical studies indicate a decreased risk of cytokine release syndrome and improved pharmacokinetics. The company plans to submit an IND application for SNS-101 by April 2023, with a Phase 1/2 trial expected to begin later in the year, pending regulatory approval.

Sensei Biotherapeutics, a leader in immuno-oncology, announced the participation of its management team in a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 11:00 a.m. ET. The event highlights Sensei's innovative approaches in developing next-generation therapeutics for cancer, notably through its TMAb™ platform that aims to enhance T cell activity against tumors. Interested parties can access a live webcast of the presentation, which will also be available for replay on the company’s website for 90 days post-event. Sensei’s lead candidate is SNS-101, targeting the VISTA checkpoint.

Sensei Biotherapeutics (Nasdaq: SNSE) announced the presentation of new preclinical data on SNS-101, a VISTA-blocking antibody, at the Next Generation Antibody Therapeutics conference in Banff from February 19-22, 2023. The Chief Scientific Officer, Dr. Edward van der Horst, will present findings indicating that SNS-101 enhances the effects of PD-1 blockade in cancer treatment and showcases favorable pharmacokinetics. A poster will also be presented during the conference, providing further insights on the therapeutic's performance. The company continues to advance its TMAb™ platform for developing innovative cancer therapies.

Sensei Biotherapeutics (Nasdaq: SNSE) announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to advance the development of SNS-101, a pH-selective VISTA-blocking antibody. This collaboration will focus on preclinical studies to explore SNS-101's mechanisms in combination with new therapies, targeting immune checkpoint resistance.

Sensei plans to submit an IND application for SNS-101 by April 2023, with clinical trials expected to start later in the year, subject to regulatory approval. The collaboration aims to validate the efficacy and safety of SNS-101.

Sensei Biotherapeutics (Nasdaq: SNSE) has entered a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab) to support a Phase 1/2 trial evaluating SNS-101, a VISTA-blocking antibody. The trial, aimed at solid tumors, will begin in 2023, pending regulatory approval. Sensei plans to submit an Investigational New Drug application by April 2023. This collaboration aims to explore the potential of SNS-101 combined with PD-1 inhibition, leveraging preclinical data suggesting strong anti-tumor activity.

eSensei Biotherapeutics (Nasdaq: SNSE) announces the closure of its Boston research site, resulting in a 40% workforce reduction, aimed at decreasing operating expenses. This strategic move is expected to extend the company's cash runway into the second half of 2025. The IND submission for their lead antibody, SNS-101, is anticipated by April 2023. The company will maintain its Rockville, Maryland facility to support ongoing programs, including SNS-101, designed to target the immune checkpoint VISTA.